BACKGROUND: Hematopoietic progenitor cells (HPCs) are able to prepare the site for incoming neoplastic cells. Among different markers of HPCs, which one should be considered the most efficient was investigated. PATIENTS AND METHODS: Five hundred and seventy-nine non-metastatic lymph nodes from 49 patients affected by invasive breast cancer were submitted to an immunohistochemical comparative analysis of hematopoietic (CD34), endothelial (CD133), mesenchymal (CD117) progenitors and vascular endothelial growth factor receptor 1 (VEGFR1, also known as Flt1). The cases with an intensity-distribution score >3 were considered as high HPC expressors. Survival univariate and multivariate analyses were performed. RESULTS: Fifteen out of the 49 patients were recorded as HPC high expressors based on the immunohistochemical VEGFR1 staining. A highly significant relationship was found between high HPC immunoexpression and the development of distant metastasis as well as the occurrence of bone localization (p<0.001). By univariate analysis, CD133 showed a highly significant value regarding metastatic localizations in the bone; by multivariate analysis, CD133 emerged as the only independent prognostic variable. CONCLUSION: CD133 expression shows a potential predictive role, thus representing a helpful tool for the management of breast cancer.
BACKGROUND: Hematopoietic progenitor cells (HPCs) are able to prepare the site for incoming neoplastic cells. Among different markers of HPCs, which one should be considered the most efficient was investigated. PATIENTS AND METHODS: Five hundred and seventy-nine non-metastatic lymph nodes from 49 patients affected by invasive breast cancer were submitted to an immunohistochemical comparative analysis of hematopoietic (CD34), endothelial (CD133), mesenchymal (CD117) progenitors and vascular endothelial growth factor receptor 1 (VEGFR1, also known as Flt1). The cases with an intensity-distribution score >3 were considered as high HPC expressors. Survival univariate and multivariate analyses were performed. RESULTS: Fifteen out of the 49 patients were recorded as HPC high expressors based on the immunohistochemical VEGFR1 staining. A highly significant relationship was found between high HPC immunoexpression and the development of distant metastasis as well as the occurrence of bone localization (p<0.001). By univariate analysis, CD133 showed a highly significant value regarding metastatic localizations in the bone; by multivariate analysis, CD133 emerged as the only independent prognostic variable. CONCLUSION:CD133 expression shows a potential predictive role, thus representing a helpful tool for the management of breast cancer.
Authors: Maria Christina Tsourlakis; Puya Khosrawi; Philipp Weigand; Martina Kluth; Claudia Hube-Magg; Sarah Minner; Christina Koop; Markus Graefen; Hans Heinzer; Corinna Wittmer; Guido Sauter; Till Krech; Waldemar Wilczak; Hartwig Huland; Ronald Simon; Thorsten Schlomm; Stefan Steurer Journal: Int J Mol Sci Date: 2015-04-16 Impact factor: 5.923
Authors: Francesca Collina; Maurizio Di Bonito; Valeria Li Bergolis; Michelino De Laurentiis; Carlo Vitagliano; Margherita Cerrone; Francesco Nuzzo; Monica Cantile; Gerardo Botti Journal: Biomed Res Int Date: 2015-10-04 Impact factor: 3.411